Enzastaurin for Patients With Metastatic Colorectal Cancer

Lilly

Status and phase: Completed; Phase 2

Conditions: Colonic Neoplasms

Treatments: Drug: Enzastaurin HCl

Study type: Interventional

Funder types: Industry

Identifiers

NCT00192114

9098

H6Q-MC-JCAR (Other Identifier)

Details and patient eligibility

About

Enzastaurin given daily to participants with colorectal cancer who have Stage 4 disease and have not received prior chemotherapy for advanced colorectal cancer

Enrollment: 28 patients

Sex: All

Ages: 19+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• diagnosed with colorectal cancer that is advanced or metastatic (has spread to other parts of the body); able to visit the doctor's office every 28 days for at least 6 months; able to swallow tablets

Exclusion criteria

• women cannot be pregnant or breastfeeding; no history of significant heart disease or any other significant medical problems as determined by the participant's physician

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

28 participants in 1 patient group

Enzastaurin HCl

Experimental group

Treatment:

Drug: Enzastaurin HCl